Genentech’s Xolair Receives FDA’s Breakthrough Therapy Designation for Food Allergies

 Genentech’s Xolair Receives FDA’s Breakthrough Therapy Designation for Food Allergies

Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)

Shots:
  •  The BT designation is based on seven clinical studies evaluating safety and efficacy for allergens including peanut, milk, egg and others
  • The BT designation for Xolair (omalizumab) is to prevent severe allergic reactions following accidental exposure to one or more foods in people with allergies
  • Genentech and Novartis are working with NIAID and the Consortium of Food Allergy Research (CoFAR) initiating a pivotal study for evaluating the efficacy and safety of Xolair in multiple food allergies. Additionally, Genentech and Novartis are working to co-develop and co-promote Xolair

Click here to read full press release/ article | Ref: Roche | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post